REG - Tissue Regenix Group - Extended distribution agreement with Arthrex, Inc.

Tissue RegenixAnnouncement

26/11/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241126:nRSZ5948Na&default-theme=true

RNS Number : 5948N  Tissue Regenix Group PLC  26 November 2024

 

Tissue Regenix Group plc

('Tissue Regenix' or the 'Company')

 

CellRight Technologies extends multi-year distribution agreement with Arthrex,
Inc.

 

Tissue Regenix (AIM: TRX), the regenerative medical devices company, announces
that its subsidiary, CellRight Technologies, LLC ("CellRight"), has amended
and extended its long-term, multi-year distribution agreement with Arthrex,
Inc. ("Arthrex"), a premier innovator of orthopaedic surgical solutions.

 

CellRight produces industry leading verified osteobiologics (engineered
materials that promote healing of fractures and bone defects) for use in
orthopaedic, spine and foot and ankle procedures. The multi-year commitment
continues to provide surgeons access to verified osteobiologics and advanced
surgical instrumentation and techniques to help influence better patient
outcomes. Arthrex and CellRight entered a marketing and sales agreement in
March 2017 and the amendment extends the term until October 2029 where it will
renew for additional periods.

 

Daniel Lee, CEO of Tissue Regenix, commented: "The extension of our long-term
distribution agreement will continue to allow physicians and patients access
to CellRight's innovative orthobiologics through the Arthrex network. Patient
outcomes are positively impacted by orthobiologic products together with the
advanced technologies and training from Arthrex. This shared vision is at the
core of this strategic partnership."

 

For more information, please contact:

 

 Tissue Regenix Group plc
 Daniel Lee, Chief Executive Officer                        via Walbrook PR

 David Cocke, Chief Financial Officer

 Cavendish Capital Markets (Nominated Adviser and Broker)
 Geoff Nash/Giles Balleny/Edward Whiley                     Tel: +44 (0) 20 7466 5000

 Nigel Birks - Life Science Specialist Sales

 Harriet Ward - ECM

 Walbrook PR (Financial PR and IR)                          Tel: +44 (0)20 7933 8780
 Alice Woodings / Lianne Applegarth                         Tissue Regenix@walbrookpr.com (mailto:TissueRegenix@walbrookpr.com)

 

About Tissue Regenix (www.tissueregenix.com (http://www.tissueregenix.com) )

Tissue Regenix is a leading medical device company in regenerative medicine.
The Company's patented decellularisation technology (dCELL®) removes DNA and
other cellular material from animal and human soft tissue, leaving an
acellular tissue scaffold that is not rejected by the patient's body and can
be used to repair diseased or damaged body structures. Current applications
address many crucial clinical needs in sports medicine, foot and ankle
injuries, and wound care.

 

In August 2017, Tissue Regenix acquired CellRight Technologies®. This
biotech company specialises in regenerative medicine and is dedicated to
developing high-quality, innovative tissue scaffolds to enhance healing
opportunities in defects created by trauma and disease. CellRight's human
tissue products may be used in spine, trauma, general orthopaedic, dental and
ophthalmological surgical procedures.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRBABJTMTMTTJI